(NASDAQ:LENS) is now up by 15.15% since yesterday’s close of 3.3 giving it a place as a top gainer in the market today. More than 22,031 shares have changed hands.
Shares of the company are trading at $3.80 which is significantly above the 50 day moving average of $2.98 and which is significantly higher than the 200 day moving average of $2.98. The 50 day moving average moved up $0.82 and the 200 day average was up $0.82.
Investors are a little more bearish on the company lately if you take a look at the increase in short interest. The firm recorded a rise in short interest of 23.93% as of August 31, 2017 from the last reporting period. Short interest increased 2,725 over that timeframe. With short interest at 14,114 and short average daily volume at 4,525, days to cover is 3.0 and the percentage of shorted shares was 0.00% on August 31.
Here are a few substantial investment firms who have updated their positions. As of the end of the quarter Ubs Group Ag had sold a total of 374 shares trimming its stake by 8.7%. The value of the investment in Presbia PLC – Ordinary Shares decreased from $13,000 to $9,000 a change of $4,000 quarter over quarter. As of quarter end Spark Investment Management LLC had acquired 4,600 shares growing its holdings by 45.5%. The value of the total investment in Presbia PLC – Ordinary Shares went from $31,000 to $33,000 a change of 6.5% quarter to quarter.
Tower Research Capital LLC (trc) reduced its position by selling 496 shares a decrease of 62.3%. Tower Research Capital LLC (trc) controls 300 shares with a value of $1,000. The value of the position overall is down by 75.0%. As of quarter end Blackrock Inc. had sold 31 shares trimming its position 3.0%. The value in dollars decreased from $3,000 to $2,000 decreasing 33.3% for the reporting period.
As of the latest earnings report the EPS was $-1.19 and is projected to be $-1.04 for the current year with 16,956,000 shares presently outstanding. Next quarter’s EPS is estimated at $-0.24 and the next full year EPS is projected to be $-0.67.
Presbia PLC, launched on February 6, 2014, is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Business’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. The Business’s lens, referred to as the microlens, is a miniature lens designed to be surgically implanted in a patient’s eye to improve that patient’s ability to see objects at close distances. The microlens is a disc shaped lens that has a refractive zone in the periphery designed to improve near vision problems associated with presbyopia and a central zone that is designed to improve distance vision. The Company intends to be a provider of corneal inlay presbyopia-correcting treatment..